CN109613128A - The measuring method of drug content in a kind of Famotidine Capsule - Google Patents
The measuring method of drug content in a kind of Famotidine Capsule Download PDFInfo
- Publication number
- CN109613128A CN109613128A CN201811353146.9A CN201811353146A CN109613128A CN 109613128 A CN109613128 A CN 109613128A CN 201811353146 A CN201811353146 A CN 201811353146A CN 109613128 A CN109613128 A CN 109613128A
- Authority
- CN
- China
- Prior art keywords
- famotidine
- methanol
- measuring method
- drug content
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229960001596 famotidine Drugs 0.000 title claims abstract description 66
- XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 title claims abstract description 64
- 238000000034 method Methods 0.000 title claims abstract description 41
- 239000003814 drug Substances 0.000 title claims abstract description 33
- 229940079593 drug Drugs 0.000 title claims abstract description 32
- 239000002775 capsule Substances 0.000 title claims abstract description 31
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims abstract description 166
- 238000001514 detection method Methods 0.000 claims abstract description 31
- 229910000402 monopotassium phosphate Inorganic materials 0.000 claims abstract description 19
- 235000019796 monopotassium phosphate Nutrition 0.000 claims abstract description 19
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 claims abstract description 19
- 238000012360 testing method Methods 0.000 claims abstract description 18
- 238000004128 high performance liquid chromatography Methods 0.000 claims abstract description 17
- 239000000825 pharmaceutical preparation Substances 0.000 claims abstract description 11
- 239000007787 solid Substances 0.000 claims abstract description 11
- 239000012046 mixed solvent Substances 0.000 claims abstract description 10
- 239000007864 aqueous solution Substances 0.000 claims abstract description 6
- 239000003085 diluting agent Substances 0.000 claims abstract description 5
- 239000000243 solution Substances 0.000 claims description 19
- 239000007788 liquid Substances 0.000 claims description 11
- 238000002360 preparation method Methods 0.000 claims description 11
- 238000010790 dilution Methods 0.000 claims description 9
- 239000012895 dilution Substances 0.000 claims description 9
- 239000013558 reference substance Substances 0.000 claims description 9
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 6
- 239000012085 test solution Substances 0.000 claims description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 4
- 239000000706 filtrate Substances 0.000 claims description 4
- 238000005259 measurement Methods 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 2
- 239000011591 potassium Substances 0.000 claims description 2
- 229910052700 potassium Inorganic materials 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 239000012071 phase Substances 0.000 description 7
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 5
- 230000000694 effects Effects 0.000 description 4
- FXJAOWANXXJWGJ-UHFFFAOYSA-N n-[4-(2-methyl-1h-imidazol-5-yl)phenyl]-n'-propan-2-ylmethanimidamide Chemical class C1=CC(NC=NC(C)C)=CC=C1C1=CN=C(C)N1 FXJAOWANXXJWGJ-UHFFFAOYSA-N 0.000 description 4
- 239000011593 sulfur Substances 0.000 description 4
- 229910052717 sulfur Inorganic materials 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 229960001380 cimetidine Drugs 0.000 description 2
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 description 2
- 229960000620 ranitidine Drugs 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 208000010470 Ageusia Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 101150056637 Hrh2 gene Proteins 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- -1 famotidine compound Chemical class 0.000 description 1
- 238000002795 fluorescence method Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000003485 histamine H2 receptor antagonist Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 238000005220 pharmaceutical analysis Methods 0.000 description 1
- 238000005375 photometry Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000006479 redox reaction Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
Landscapes
- Physics & Mathematics (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention provides a kind of measuring methods of drug content in Famotidine Capsule, using the mixed solvent of potassium dihydrogen phosphate and methanol as mobile phase, using methanol as diluent, are detected using high performance liquid chromatography (HPLC), Detection wavelength 270nm.The mixed solvent of the potassium dihydrogen phosphate and methanol by mass percent concentration be 0.125% potassium dihydrogen phosphate aqueous solution and methanol by volume (60-80): (35-45) is configured.Measuring method of the present invention, it can precise determination famotidine solid pharmaceutical preparation content, it solves and the problems such as detection efficiency is low, detection error is big and accuracy is not high exists in the prior art, while important references can be provided to improve detection level cloud test accuracy in famotidine solid pharmaceutical preparation.
Description
Technical field
The present invention relates to a kind of surveys of drug content in Pharmaceutical Analysis detection technique field more particularly to Famotidine Capsule
Determine method.
Background technique
Famotidine (Famotidine, FAM) is the 3rd generation H2 receptor antagonist occurred after Cimetidine and ranitidine
Medicine, action intensity is 30-100 times bigger than Cimetidine, 6-10 times bigger than ranitidine, for treating taste-blindness rate
With other acute gastrointestinal diseases, have to stomach lining H2 receptor affinity is high, effect is good, adverse reaction is few, patient tolerability
The features such as well and not influencing other medicines metabolism, clinical application is more and more extensive.But famotidine absorbs not exclusively in gastrointestinal tract,
Oral administration biaavailability is only 40%-50%.Therefore, widespread practice is that famotidine is made to gastric retention solid pharmaceutical preparation, is prolonged
Its long residence time in stomach, to achieve the purpose that the curative effect for increasing drug.
Famotidine solid pharmaceutical preparation uniformity of dosage units is using ultraviolet-visible in 2015 editions Chinese Pharmacopoeias of present
Light photometry calculates uniformity of dosage units with absorption coefficient, and this analysis method human intervention factor is more, testing staff if you need to
Multiple batches of continuous detection, may cause inefficiency, be easy to appear the unfavorable factors such as mistake.
In addition, publication CN10652578A discloses sulfur-bearing bisfentidine class drug in a kind of measurement drug
The method of content, main technical schemes are to utilize fluorescence method indirect determination sulfur-bearing bisfentidine class reproducibility drug, benefit
Redox reaction occurs with oxidant N- bromo-succinimide and sulfur-bearing bisfentidine class reproducibility drug, by sulfur-bearing
Sulphur in bisfentidine class reproducibility drug is oxidized to sulfoxide, and selectivity is stronger, reacts more sensitive.And it discloses specially
Sharp CN10325719A discloses a kind of measurement brufen/famotidine compound preparation content method, and method is washed with gradient
It is de-, it is cumbersome by the concentration proportioning for constantly changing mobile phase to a certain degree in the same analytical cycle, it easily causes
Baseline drift, analytical cycle is too long (could terminate within about 35 minutes), equally exists that detection efficiency is low, detection error is big, accuracy
The defects of not high.
Summary of the invention
Required the technical issues of solving of the invention is that there are detection error, accuracy be not high for existing detection technique
Defect provides a kind of measuring method of drug content in Famotidine Capsule.
To achieve the above object, the invention adopts the following technical scheme:
The present invention provides a kind of measuring method of drug content in Famotidine Capsule, with the mixed of potassium dihydrogen phosphate and methanol
Bonding solvent is mobile phase, using methanol as diluent, is detected using high performance liquid chromatography (HPLC), Detection wavelength is
270nm。
Further, in the Famotidine Capsule in the measuring method of drug content, the potassium dihydrogen phosphate and
The potassium dihydrogen phosphate aqueous solution and methanol (60- by volume that the mixed solvent of methanol is 0.125% by mass percent concentration
80): (35-45) is configured.
Further, in the Famotidine Capsule in the measuring method of drug content, described 0.125% phosphoric acid
Dihydro aqueous solutions of potassium and methanol are 70:30 by volume.
Further, in the Famotidine Capsule in the measuring method of drug content, the detector bar of the HPLC
Part is as follows:
Chromatographic column: 250 × 4.6mm of C18 column；
Mobile phase: the mixed solvent of 0.125% potassium dihydrogen phosphate and methanol；
Flow velocity: 1.2-1.8ml/min；
Detection wavelength: 270nm；
Sample volume: 15-25 μ l；
Column temperature: 26-34 DEG C；
System suitability: number of theoretical plate is not less than 1000.
Further, in the Famotidine Capsule in the measuring method of drug content, the detection side of the HPLC
Method is as follows:
(1) preparation of reference substance solution: taking famotidine reference substance about 10mg, accurately weighed, adds methanol to be configured to 1ml and contains
The solution of famotidine 10ug, both；
(2) preparation of test solution: precision weighs famotidine solid pharmaceutical preparation fine powder 0.1g, weighed, sets 100ml measuring bottle
In, add methanol dilution to scale, shakes up；Precision measures 1ml, sets in 100ml measuring bottle, adds methanol solution to scale, shake up, both
?；
(3) measuring method: it is accurate respectively to measure contrast solution and each 20ul of test solution, high performance liquid chromatograph is injected,
Measure famotidine content.
It is further preferred that in the Famotidine Capsule in the measuring method of drug content, the famotidine
Methanol solution preparation method are as follows: precision weighs Famotidine Capsule about 165mg, 171mg, 177mg (each 3 parts), sets respectively
In 100ml measuring bottle, scale is dissolved and be diluted to methanol respectively, is shaken up, filtered；Precision measures subsequent filtrate 5ml, sets 100ml amount
Bottle in, add methanol solution be diluted to scale to get.
Further, in the Famotidine Capsule in the measuring method of drug content, the detector bar of the HPLC
Flow velocity described in part is 1.5ml/min, and Detection wavelength 270nm, column temperature is 30 DEG C.
The present invention by adopting the above technical scheme, compared with prior art, has the following technical effect that
The measuring method of drug content in Famotidine Capsule of the present invention examines famotidine using high performance liquid chromatography
The uniformity of dosage units of famotidine in capsule, using potassium dihydrogen phosphate/methanol as mobile phase, using methanol as diluent, precise determination
Famotidine solid pharmaceutical preparation content solves and exists in the prior art that detection efficiency is low, detection error is big and accuracy is not high
The problems such as, while important references can be provided to improve detection level cloud test accuracy in famotidine solid pharmaceutical preparation.
Specific embodiment
The present invention provides a kind of measuring method of drug content in Famotidine Capsule, with potassium dihydrogen phosphate and methanol
Mixed solvent is mobile phase, using methanol as diluent, is detected using high performance liquid chromatography (HPLC), Detection wavelength is
270nm.The mixed solvent of the potassium dihydrogen phosphate and methanol is water-soluble by the potassium dihydrogen phosphate that mass percent concentration is 0.125%
Liquid and methanol is by volume (60-80): (35-45) is configured；Preferably, described 0.125% potassium dihydrogen phosphate aqueous solution
It is by volume 70:30 with formaldehyde.The measuring method uses high performance liquid chromatography, efficiently, accurately, reduces error, while can
Important references are provided to improve detection level cloud test accuracy in famotidine solid pharmaceutical preparation.
As an optimal technical scheme, the testing conditions of the HPLC are as follows: chromatographic column: 250 × 4.6mm of C18 column；Stream
Dynamic phase: the mixed solvent of 0.125% potassium dihydrogen phosphate and methanol；Flow velocity: 1.2-1.8ml/min；Detection wavelength: 270nm；Sample introduction
Amount: 15-25 μ l；Column temperature: 26-34 DEG C；Preferably, flow velocity described in the testing conditions of the HPLC is 1.5ml/min, detects wave
A length of 270nm, column temperature are 30 DEG C.
As an optimal technical scheme, the detection method of the HPLC is as follows: (1) preparation of reference substance solution: following the example of
Fourth reference substance about 10mg is not replaced, it is accurately weighed, add methanol to be configured to the solution of 1ml 10ug containing famotidine, both；(2) for examination
The preparation of product solution: precision weighs famotidine solid pharmaceutical preparation fine powder 0.1g, weighed, sets in 100ml measuring bottle, adds methanol dilution extremely
Scale shakes up；Precision measures 1ml, sets in 100ml measuring bottle, adds methanol solution to scale, shakes up, both obtained；(3) measuring method: respectively
Precision measures contrast solution and each 20ul of test solution, injects high performance liquid chromatograph, measures famotidine content.
The present invention is described in more detail below by specific embodiment, for a better understanding of the present invention,
But following embodiments are not intended to limit the scope of the invention.
The measurement of drug content in embodiment Famotidine Capsule
(1) reagent is shown in Table 1:
1 reagent source of table
| Title | Manufacturer | Remarks |
| Famotidine Capsule | Upper Hisense's friendship everything medicine company | Lot number -51161001 |
| Famotidine control | Middle inspection institute | - |
| Famotidine raw material | Chongqing Qingyang pharmaceutcal corporation, Ltd | Lot number -0400-130501 |
| Potassium dihydrogen phosphate | China Tech skill (Jiangsu) Co., Ltd forever | It analyzes pure |
| Methanol | Merck company | Chromatographic grade |
(2) testing conditions of HPLC are as follows:
Chromatographic column: 250 × 4.6mm of C18 column；
Mobile phase: the mixed solvent of 0.125% potassium dihydrogen phosphate and methanol；
Flow velocity: 1.5ml/min；
Detection wavelength: 270nm；
Sample volume: 15-25 μ l；
Column temperature: 26-34 DEG C；
System suitability: number of theoretical plate is not less than 1000.
Further, in the Famotidine Capsule in the measuring method of drug content, the detection side of the HPLC
Method is as follows:
(1) preparation of comparison liquid: precision weighs famotidine reference substance about 20mg, sets in 100ml measuring bottle, is dissolved with methanol
And it is diluted to scale, it shakes up；Precision measures 5ml, sets in 100ml measuring bottle, with methanol to scale, shakes up, and 20ul is taken to inject liquid phase
Chromatograph；
(2) preparation of material liquid: precision weighs famotidine raw material about 20mg, sets in 100ml measuring bottle, simultaneously with methanol dissolution
It is diluted to scale, is shaken up；Precision measures 5ml, sets in 100ml measuring bottle, with methanol dilution to scale, shakes up, and 20ul is taken to inject liquid
Chromatography；
(3) precision weighs Famotidine Capsule about 165mg, 171mg, 177mg (each 3 parts), is set in 100ml measuring bottle respectively,
Scale is dissolved and be diluted to methanol respectively, is shaken up, is filtered；Precision measures subsequent filtrate 5ml, sets in 100ml measuring bottle, adds methanol solution
Be diluted to scale to get.
Method validation is ensure content assaying method of the present invention scientific, reasonable, feasible, and inventor has carried out a series of
Experimental study and investigation.The following are the chromatographic conditions of the measuring method of drug content in Famotidine Capsule of the present invention to determine
Afterwards, its experiment for measuring effect is verified.
1, accuracy, precision, specificity experiment
Precision weighs Famotidine Capsule about 165mg, 171mg, 177mg (each 3 parts), is set in 100ml measuring bottle respectively, respectively
Scale is dissolved and be diluted to methanol, is shaken up, and is filtered；Precision measures subsequent filtrate 5ml, sets in 100ml measuring bottle, methanol solution is added to dilute
To scale to get, take 20ul inject liquid chromatograph.It is measured record chromatogram by embodiment chromatographic condition, records chromatography
The peak area at famotidine peak, testing result are shown in Table 1 in figure:
1 accuracy of table, precision, specificity experimental result
The result shows that: the average recovery rate of peak area is 100.2%, RSD 0.31%, shows the accuracy of this method
High, high-specificity, instrument precision are good.
2, the precision of famotidine
Precision weighs famotidine reference substance about 20mg, sets in 100ml measuring bottle, and scale is dissolved and be diluted to methanol, is shaken
It is even；Precision measures 5ml, sets in 100ml measuring bottle, with methanol to scale, shakes up, and 20ul is taken to inject liquid chromatograph；By embodiment
Chromatographic condition is measured record chromatogram, testing result such as table 2:
The precision experiment result of 2 famotidine of table
3, the precision of measuring method
Test liquid: precision weighs famotidine raw material about 25mg, sets in 50ml measuring bottle, is dissolved with methanol and is diluted to quarter
Degree, shakes up；Precision measures 1ml, sets in 100ml measuring bottle, with methanol dilution to scale, shakes up；Precision measures 1ml, sets 100ml amount
In bottle, with methanol dilution to scale, shake up；Precision measures 3ml, sets in 10ml measuring bottle, methanol dilution to scale shakes up, takes
20ul injects liquid chromatograph；It is measured record chromatogram by embodiment chromatographic condition, testing result such as table 3:
3 precision testing result of table
4, quantitative limit is tested
Stock solution: taking famotidine reference substance about 20mg, accurately weighed, sets in 100ml measuring bottle, methanol is added to dissolve and dilute
To scale, shake up.5ml is taken again, is set in 50ml volumetric flask, is added methanol dilution to scale, is shaken up, as stock solution.
Quantitative limit test liquid: it takes stock solution 3ml into 200ml volumetric flask, adds methanol dilution to scale.20ul is taken to inject liquid
Chromatography；It is measured record chromatogram by embodiment chromatographic condition, testing result such as table 4:
4 quantitative limit testing result of table
| Quantitative limit (ng) | 0.3023 |
As can be seen that this method accuracy, precision, specificity meet from above-mentioned each summary sheet and each detection data
Regulation, average recovery rate 100.2%, RSD 0.31%；Comply with standard.This method can apply to measure famotidine
The practice examining of famotidine content in capsule solves and exists in the prior art that detection efficiency is low, detection error is big and quasi-
The problems such as exactness is not high, while can be provided for detection level cloud test accuracy in improvement famotidine solid pharmaceutical preparation important
With reference to.
Specific embodiments of the present invention are described in detail above, but it is merely an example, the present invention is simultaneously unlimited
It is formed on particular embodiments described above.To those skilled in the art, any couple of present invention carries out equivalent modifications and
Substitution is also all among scope of the invention.Therefore, without departing from the spirit and scope of the invention made by equal transformation and
Modification, all should be contained within the scope of the invention.
Claims (7)
1. the measuring method of drug content in a kind of Famotidine Capsule, which is characterized in that with the mixed of potassium dihydrogen phosphate and methanol
Bonding solvent is mobile phase, using methanol as diluent, is detected using high performance liquid chromatography (HPLC), Detection wavelength is
270nm。
2. the measuring method of drug content in Famotidine Capsule according to claim 1, which is characterized in that the phosphoric acid
The potassium dihydrogen phosphate aqueous solution and methanol that the mixed solvent of potassium dihydrogen and methanol is 0.125% by mass percent concentration press volume
Than (60-80): (35-45) is configured.
3. the measuring method of drug content in Famotidine Capsule according to claim 2, which is characterized in that described
0.125% potassium dihydrogen phosphate aqueous solution and formaldehyde is 60:80 by volume.
4. the measuring method of drug content in Famotidine Capsule according to claim 1, which is characterized in that the HPLC
Testing conditions it is as follows:
Chromatographic column: 250 × 4.6mm of C18 column；
Mobile phase: the mixed solvent of 0.125% potassium dihydrogen phosphate and methanol；
Flow velocity: 1.2-1.8ml/min；
Detection wavelength: 270nm；
Sample volume: 15-25 μ l；
Column temperature: 26-34 DEG C；
System suitability: number of theoretical plate, which is pressed, is not less than 1000.
5. the measuring method of drug content in Famotidine Capsule according to claim 1, which is characterized in that the HPLC
Detection method it is as follows:
(1) preparation of reference substance solution: taking famotidine reference substance about 10mg, accurately weighed, adds methanol to be configured to 1ml and contains method not
For the solution of fourth 10ug, both；
(2) preparation of test solution: precision weighs famotidine solid pharmaceutical preparation fine powder 0.1g, weighed, sets in 100ml measuring bottle,
Add methanol dilution to scale, shakes up；Precision measures 1ml, sets in 100ml measuring bottle, adds methanol solution to scale, shakes up, both obtained；
(3) measuring method: it is accurate respectively to measure contrast solution and each 20ul of test solution, inject high performance liquid chromatograph, measurement
Famotidine content.
6. the measuring method of drug content in Famotidine Capsule according to claim 5, which is characterized in that the method is not
For the methanol solution preparation method of fourth are as follows: precision weighs Famotidine Capsule about 165mg, 171mg, 177mg (each 3 parts), respectively
It sets in 100ml measuring bottle, dissolves and be diluted to scale with methanol respectively, shake up, filter；Precision measures subsequent filtrate 5ml, sets 100ml
In measuring bottle, add methanol solution be diluted to scale to get.
7. the measuring method of drug content in Famotidine Capsule according to claim 1, which is characterized in that the HPLC
Testing conditions described in flow velocity be 1.5ml/min, Detection wavelength 270nm, column temperature be 30 DEG C.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811353146.9A CN109613128A (en) | 2018-11-14 | 2018-11-14 | The measuring method of drug content in a kind of Famotidine Capsule |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811353146.9A CN109613128A (en) | 2018-11-14 | 2018-11-14 | The measuring method of drug content in a kind of Famotidine Capsule |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109613128A true CN109613128A (en) | 2019-04-12 |
Family
ID=66004374
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811353146.9A Pending CN109613128A (en) | 2018-11-14 | 2018-11-14 | The measuring method of drug content in a kind of Famotidine Capsule |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109613128A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110988169A (en) * | 2019-12-12 | 2020-04-10 | 南京正济医药研究有限公司 | High performance liquid chromatography analysis and detection method for formaldehyde content in ranitidine hydrochloride |
| CN112763625A (en) * | 2020-12-30 | 2021-05-07 | 江苏正济药业股份有限公司 | Detection method of famotidine and related substances thereof |
| CN114791469A (en) * | 2022-04-25 | 2022-07-26 | 四川启源药业有限公司 | Method for detecting content of vitamin C in famotidine injection |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103257190A (en) * | 2013-04-15 | 2013-08-21 | 南京艾德凯腾生物医药有限责任公司 | Method for measuring buprofen/famotidine compound preparation content |
-
2018
- 2018-11-14 CN CN201811353146.9A patent/CN109613128A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103257190A (en) * | 2013-04-15 | 2013-08-21 | 南京艾德凯腾生物医药有限责任公司 | Method for measuring buprofen/famotidine compound preparation content |
Non-Patent Citations (4)
| Title |
|---|
| 叶海英 等: "HPLC法测定法莫替丁微乳口服液的含量", 《广东药学学院》 * |
| 吕娟丽 等: "高效液相色谱法测定法莫替丁含量", 《解放军药学学报》 * |
| 罗国平 等: "HPLC法测定复方法莫替丁胃内漂浮型缓释片中法莫替丁的含量", 《应用化工》 * |
| 谈珺珺 等: "反相高效液相色谱法测定法莫替丁片含量—中国药典(2000版)和美国药典(26版)方法的比较", 《安徽医药》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110988169A (en) * | 2019-12-12 | 2020-04-10 | 南京正济医药研究有限公司 | High performance liquid chromatography analysis and detection method for formaldehyde content in ranitidine hydrochloride |
| CN112763625A (en) * | 2020-12-30 | 2021-05-07 | 江苏正济药业股份有限公司 | Detection method of famotidine and related substances thereof |
| CN114791469A (en) * | 2022-04-25 | 2022-07-26 | 四川启源药业有限公司 | Method for detecting content of vitamin C in famotidine injection |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109613128A (en) | The measuring method of drug content in a kind of Famotidine Capsule | |
| CN103698424B (en) | Detecting method of detecting organic solvent in slightly-soluble aluminum salt drug | |
| CN103076410A (en) | Dissolution rate detection method for simvastatin | |
| CN109387587A (en) | A kind of detection method of L-Arginine enantiomter | |
| CN101285803B (en) | Qualitative analysis detection method for low polarity sugar-reducing chemical medicament in traditional Chinese medicine | |
| CN105987961A (en) | Detection method of levetiracetam in breast milk | |
| CN105606717B (en) | The detection method in Buddhist nun's bulk drug about material is replaced in the life of two p-methyl benzenesulfonic acid edge | |
| CN106525994A (en) | Method for determination of related substances of paracetamol and tramadol hydrochloride capsules | |
| CN105675754B (en) | The method of high effective liquid chromatography for measuring Li Gelieting enantiomter contents | |
| CN104535690B (en) | Method for measuring content of cinnarizine in cinnarizine solid preparation | |
| CN108037230A (en) | A kind of analysis method of precise determination Allopurinol solid pharmaceutical preparation drug content | |
| CN101285802B (en) | Qualitative analysis detection method for high polarity sugar-reducing chemical medicament in traditional Chinese medicine | |
| CN1790013B (en) | A method for simultaneous determination of protocatechuic acid and 5-hydroxymethylfurfural in Shengmai injection | |
| CN115236255B (en) | Method for detecting related substances of loxoprofen sodium | |
| CN113466360B (en) | Azilsartan 6 related substance detection method | |
| CN109580834A (en) | Detection method in relation to substance in a kind of pharmaceutical preparation containing C14H25N4NaO11P2 | |
| CN108169362B (en) | Method for separating carbamazepine and related substances by liquid chromatography | |
| CN104965031B (en) | Content measuring method for compound ketoprofen and omeprazole sustained-release capsules | |
| CN111948313B (en) | Method for determining content of trimethoprim and multiple sulfanilamide drugs in drug and application thereof | |
| CN107449844B (en) | Method for determining dissolution rate of dimercaptosuccinic acid preparation | |
| CN108872406A (en) | HPLC analyzing detecting method in relation to substance in a kind of L-aminobutanedioic acid bulk pharmaceutical chemicals | |
| CN102109501A (en) | Method for detecting related substances in quinapril hydrochloride and hydrochlorothiazide composition | |
| Shao et al. | Flow injection chemiluminescence determination of levofloxacin in medicine and biological fluids based on its enhancing effect on luminol–H2O2 reaction | |
| CN107884496B (en) | Method for determining content of succinic acid in trelagliptin succinate | |
| CN111044635A (en) | Method for analyzing content of mecobalamin particles |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20190412 |